Movement Disorders, Parkinson's Disease
Read Time: 2 mins

Two Decades of Evolving Care with Pump Therapies – What have we Learned?

Copy Link
Published Online: Jul 15th 2012 European Neurological Review, 2012;7(Suppl. 1):5–7 DOI:
Authors: Andrew Lees
Quick Links:
Article Information

Since the discovery that the gold standard treatment in Parkinson’s disease (PD), oral levodopa, contributes to motor fluctuations, the treatment strategy of delivering dopaminergic drugs in a continuous manner has been investigated. Motor fluctuations are believed to be the result of a combination of progressive denervation of the striatum with advancing disease and erratic gastric emptying with oral levodopa, which leads to peaks and troughs in plasma levodopa concentration and thus pulsatile stimulation of dopaminergic neurons. Methods have been developed to provide continuous dopaminergic stimulation, such as the delivery of apomorphine by subcutaneous infusion and levodopa/carbidopa by intestinal gel infusion. These therapies have been shown to significantly reduce ‘off’ time and improve motor fluctuations, and therefore have been a major advance in the management of PD.


Parkinson’s disease, levodopa, continuous dopaminergic stimulation, subcutaneous apomorphine infusion, levodopa/carbidopa intestinal gel infusion


Lessons Learned about Levodopa
Motor fluctuations in Parkinson’s disease (PD) were described as early as 1969 by Cotzias et al.1 Subsequent studies showed that many motor fluctuations were associated with low plasma levodopa levels (troughs) that occurred between oral doses of levodopa.2This phenomenon was called the end-of-dose deterioration or ‘wearing-off’ effect. In the 1970s and 1980s, clinical pharmacology research provided a great deal of information about oral levodopa and its relationship to the ‘wearing-off’ effect.

Levodopa benefits the patient from the very first dose but requires a few weeks to reach optimum effect. The stronger the initial response to the drug, the more prominent the subsequent motor fluctuations.3 Increasing the dose of levodopa has been shown to prolong the duration of benefit, but does not increase the amplitude of response, and generally, the motor response wears off when plasma levodopa level drops to 50 % of the peak level, irrespective of the duration of benefit.4

The ‘On-off’ Phenomenon
The most common manifestation of the ‘on-off’ phenomenon is inter-dose or peak-dose dyskinesia, which occurs at a rate of approximately 10 % per treatment year. As a result, after 10 years of oral levodopa treatment, almost all patients who are on significant doses of levodopa will have developed some dyskinesias.5 Another form of dyskinesia is biphasic dyskinesias, which are much less frequent, partly because modern pharmacotherapies help to reduce their severity. These are particularly troublesome in young-onset patients, are extremely disabling and much more difficult to treat than peak-dose dyskinesias. ‘Off’-period dystonia is another form that is often forgotten. Therefore, dyskinesias are not just one simple pattern of peak-dose dyskinesias.

In the 1980s, it was not clear whether ‘off’ periods were treatable. One theory was that during ‘off’ periods, patients were unresponsive to dopaminergic drugs, even at a high dose. However, this view began to be challenged by studies using continuous delivery of dopaminergic drugs.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:

Andrew Lees has acted as a consultant for Genus and has served on the advisory boards of Novartis, Teva, Meda, Boehringer Ingelheim, GlaxoSmithKline (GSK), Ipsen, Lundbeck, Allergan, Orion, Bial, Noscira and Roche. He has received honoraria from Novartis, Teva, Meda, Boehringer Ingelheim, GSK, Ipsen, Lundbeck, Allergan, Orion, Bial, Noscira and Roche, as well as grants from PSP Association and Weston Trust – The Reta Lila Howard Foundation.


Andrew Lees, Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London, WC1N 1PJ, UK. E:


The V International Forum on Parkinson’s Disease (Helsinki, Finland, 6–7 May 2011) was funded by an unrestricted educational grant from Abbott. Abbott funded the development of this supplement by ESP Bioscience (Crowthorne, UK). Emily Chu and Nicole Meinel of ESP Bioscience provided medical writing and editorial support to the author in the development of this publication. Abbott had the opportunity to review and comment on the publication’s content; however, all decisions regarding content were made by the author.




  1. Cotzias GC, Papavasiliou PS, Gellene R, Modification of Parkinsonism – chronic treatment with L-dopa, N Engl J Med, 1969;280:337–45.
  2. Tolosa ES, Martin WE, Cohen HP, Jacobson RL, Patterns of clinical response and plasma dopa levels in Parkinson’s disease, Neurology, 1975;25:177–83.
  3. Kempster PA, Williams DR, Selikhova M, et al., Patterns of levodopa response in Parkinson’s disease: a clinicopathological study, Brain, 2007;130:2123–8.
  4. Kempster PA, Frankel JP, Bovingdon M, et al., Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 1989;52:718–23.
  5. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y, Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial, Neurology, 2001;57:1687–94.
  6. Hardie RJ, Lees AJ, Stern GM, On-off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study, Brain, 1984;107:487–506.
  7. Obeso JA, Luquin MR, Martínez-Lage JM, Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease, Lancet, 1986;1:467–70.
  8. Stibe CM, Kempster PA, Lees AJ, Stern GM, Subcutaneous apomorphine in parkinsonian on-off oscillations, Lancet, 1988;331:403–6.
  9. Acland KM, Churchyard A, Fletcher CL, et al., Panniculitis in association with apomorphine infusion, Br J Dermatol, 1998;138:480–2.
  10. Christmas TJ, Kempster PA, Chapple CR, et al., Role of subcutaneous apomorphine in parkinsonian voiding dysfunction, Lancet, 1988;2:1451–3.
  11. Syed N, Murphy J, Zimmerman T Jr, et al., Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease, Mov Disord, 1998;13:336–8.
  12. Kurth MC, Tetrud JW, Irwin I, et al., Oral levodopa/carbidopa solution versus tablets in Parkinson’s patients with severe fluctuations: a pilot study, Neurology, 1993;43:1036–9.
  13. Sage JI, Trooskin S, Sonsalla PK, et al., Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism, Ann Neurol, 1988;24:87–9.
  14. Quinn N, Parkes JD, Marsden CD, Control of on/off phenomenon by continuous intravenous infusion of levodopa, Neurology, 1984;34:1131–6.
  15. Nyholm D, Askmark H, Gomes-Trolin C, et al., Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets, Clin Neuropharmacol, 2003;26:156–63.
  16. Antonini A, Isaias IU, Canesi M, et al., Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome, Mov Disord, 2007;22:1145–9.
  17. Nyholm D, Nilsson Remahl AI, Dizdar N, et al., Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease, Neurology, 2005;64:216–23.
  18. Kempster PA, O’Sullivan SS, Holton JL, et al., Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study, Brain, 2010;133:1755–62.

Further Resources

Share this Article
Related Content In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72